Juin Subir Kumar, Pushpakumar Sathnur, Sen Utpal
Department of Physiology, University of Louisville School of Medicine, Louisville, KY, United States.
Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, KY, United States.
Front Pharmacol. 2024 May 21;15:1369408. doi: 10.3389/fphar.2024.1369408. eCollection 2024.
Chronic hyperglycemia-induced oxidative stress plays a crucial role in the development of diabetic nephropathy (DN). Moreover, adverse extracellular matrix (ECM) accumulation elevates renal resistive index leading to progressive worsening of the pathology in DN. Nimbidiol is an alpha-glucosidase inhibitor, isolated from the medicinal plant, 'neem' () and reported as a promising anti-diabetic compound. Previously, a myriad of studies demonstrated an anti-oxidative property of a broad-spectrum neem-extracts in various diseases including diabetes. Our recent study has shown that Nimbidiol protects diabetic mice from fibrotic renal dysfunction in part by mitigating adverse ECM accumulation. However, the precise mechanism remains poorly understood.
The present study aimed to investigate whether Nimbidiol ameliorates renal injury by reducing oxidative stress in type-1 diabetes. To test the hypothesis, wild-type (C57BL/6J) and diabetic Akita (C57BL/6-/J) mice aged 10-14 weeks were used to treat with saline or Nimbidiol (400 μg kg day) for 8 weeks.
Diabetic mice showed elevated blood pressure, increased renal resistive index, and decreased renal vasculature compared to wild-type control. In diabetic kidney, reactive oxygen species and the expression levels of 4HNE, p22phox, Nox4, and ROMO1 were increased while GSH: GSSG, and the expression levels of SOD-1, SOD-2, and catalase were decreased. Further, eNOS, ACE2, Sirt1 and IL-10 were found to be downregulated while iNOS and IL-17 were upregulated in diabetic kidney. The changes were accompanied by elevated expression of the renal injury markers viz., lipocalin-2 and KIM-1 in diabetic kidney. Moreover, an upregulation of p-NF-κB and a downregulation of IkBα were observed in diabetic kidney compared to the control. Nimbidiol ameliorated these pathological changes in diabetic mice.
Altogether, the data of our study suggest that oxidative stress largely contributes to the diabetic renal injury, and Nimbidiol mitigates redox imbalance and thereby protects kidney in part by inhibiting NF-κB signaling pathway in type-1 diabetes.
慢性高血糖诱导的氧化应激在糖尿病肾病(DN)的发生发展中起关键作用。此外,细胞外基质(ECM)的不良积累会提高肾阻力指数,导致DN病理状况逐渐恶化。尼姆比二醇是一种α-葡萄糖苷酶抑制剂,从药用植物“印楝”中分离得到,据报道是一种很有前景的抗糖尿病化合物。此前,大量研究表明,包括糖尿病在内的各种疾病中,广谱印楝提取物具有抗氧化特性。我们最近的研究表明,尼姆比二醇部分通过减轻不良的ECM积累,保护糖尿病小鼠免受纤维化肾功能障碍的影响。然而,确切机制仍知之甚少。
本研究旨在探讨尼姆比二醇是否通过减轻1型糖尿病中的氧化应激来改善肾损伤。为验证这一假设,选用10 - 14周龄的野生型(C57BL/6J)和糖尿病阿基塔(C57BL/6 - /J)小鼠,用生理盐水或尼姆比二醇(400μg/kg/天)治疗8周。
与野生型对照相比,糖尿病小鼠血压升高、肾阻力指数增加且肾血管减少。在糖尿病肾脏中,活性氧以及4 - 羟基壬烯醛(4HNE)、p22吞噬细胞氧化酶(p22phox)、NADPH氧化酶4(Nox4)和含巯基氧化还原调节蛋白1(ROMO1)的表达水平升高,而谷胱甘肽(GSH)与氧化型谷胱甘肽(GSSG)的比值以及超氧化物歧化酶1(SOD - 1)、超氧化物歧化酶2(SOD - 2)和过氧化氢酶的表达水平降低。此外,在糖尿病肾脏中发现内皮型一氧化氮合酶(eNOS)、血管紧张素转换酶2(ACE2)、沉默信息调节因子1(Sirt1)和白细胞介素10(IL - 10)下调,而诱导型一氧化氮合酶(iNOS)和白细胞介素17(IL - 17)上调。这些变化伴随着糖尿病肾脏中肾损伤标志物即脂质运载蛋白2和肾损伤分子1(KIM - 1)表达的升高。此外,与对照相比,糖尿病肾脏中磷酸化核因子κB(p - NF - κB)上调,而核因子κB抑制蛋白α(IkBα)下调。尼姆比二醇改善了糖尿病小鼠的这些病理变化。
总之,我们研究的数据表明氧化应激在很大程度上导致糖尿病肾损伤,而尼姆比二醇减轻氧化还原失衡,从而在1型糖尿病中部分通过抑制核因子κB信号通路保护肾脏。